{"article_title": "Better Buy: GlaxoSmithKline vs. AstraZeneca -- The Motley Fool", "article_keywords": ["fool", "video", "buy", "revenue", "motley", "work", "sales", "replace", "better", "vs", "astrazeneca", "glaxosmithkline", "williamson", "strong", "struggling"], "article_url": "http://www.fool.com/investing/general/2014/07/09/better-buy-glaxosmithkline-vs-astrazeneca.aspx", "article_text": "AstraZeneca (NYSE:AZN) and GlaxoSmithKline (NYSE:GSK) have a lot of work ahead. Both are struggling to find revenue to replace sales from aging blockbusters (Nexium and Crestor for AstraZeneca and Advair for GlaxoSmithKline), although both also have some exciting pipeline prospects that may cushion that blow. Both also pay strong dividends, which may make them an intriguing play for income investors.\n\nSo, when comparing the two British pharmas, which is the better buy?\n\nIn the video below, Motley Fool health care analysts Michael Douglass and David Williamson answer.", "article_metadata": {"publish_time": "17:00", "description": "Which is the better buy?", "ResponsiveALP": "1Ses_control-21_control_100", "author": "Michael Douglass and Dave Williamson", "promo": "Which is the better buy?", "twitter": {"title": "Better Buy: GlaxoSmithKline vs. AstraZeneca --  The Motley Fool", "description": "Which is the better buy?", "site": "@themotleyfool"}, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "og": {"site_name": "The Motley Fool", "description": "Which is the better buy?", "title": "Better Buy: GlaxoSmithKline vs. AstraZeneca --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/07/09/better-buy-glaxosmithkline-vs-astrazeneca.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "headline": "Better Buy: GlaxoSmithKline vs. AstraZeneca", "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "e28a8ad4-05ca-11e4-ab7b-0050569d32b9", "pitch": 823, "date": "2014-07-09T21:00:00Z", "gsa_date": "2014 07 09", "tickers": "GSK,AZN", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fdbdfe\"", "article_summary": "AstraZeneca (NYSE:AZN) and GlaxoSmithKline (NYSE:GSK) have a lot of work ahead.\nIn the video below, Motley Fool health care analysts Michael Douglass and David Williamson answer.\nBoth are struggling to find revenue to replace sales from aging blockbusters (Nexium and Crestor for AstraZeneca and Advair for GlaxoSmithKline), although both also have some exciting pipeline prospects that may cushion that blow.\nSo, when comparing the two British pharmas, which is the better buy?\nBoth also pay strong dividends, which may make them an intriguing play for income investors."}